BASTIDE LE CONFORT MEDICAL in the news

BASTIDE LE CONFORT MEDICAL disclosed its share and voting rights breakdown as of September 30, 2026, including ordinary and preference shares, along with theoretical and exercisable voting rights.

Bastide le Confort Medical updated its share capital and voting rights structure, reporting 7,468,749 shares and over 11 million theoretical voting rights as of September 30, 2026.

Bastide Le Confort Médical's stock is currently undervalued at •20.00, despite an intrinsic value of •26.28 and an expected 46% profit growth over the next two years.

Bastide Le Confort Médical achieved a turnover of 482.9 million euros by June 30, 2026, marking a 7.6% comparable growth, and exceeding its financial targets.

Bastide le Confort Medical updated its capital structure and voting rights, reporting 7,468,749 shares and over 11.5 million exercisable voting rights as of August 31, 2026.

The document provides the Enterprise Value to EBIT forward for Bastide Le Confort Medical SA, ticker EURONEXT:BLC.

Bastide's 2025-2026 annual revenue grew by 7.6% to 482.9 M€ (excluding EXPERF), surpassing its objectives and maintaining a strong operating margin target.

Bastide Le Confort Médical exceeded its 2026 revenue targets with €482.9 million despite divestitures and reimbursement cuts, driven by strong growth in home health services and respiratory activities.

Bastide Le Confort Médical's revenue grew by 7.6% to 483 million euros in fiscal year 2025-2026, and the company projects crossing the 500 million euro mark next year.

Oddo BHF reiterates its "Outperform" rating and 310 EUR price target for Bastide, citing better-than-expected revenue and strong organic growth.

Bastide Group achieved strong revenue growth in Q4 and annually for 2025-2026, confirming its operating margin target.

Bastide Le Confort Médical recorded a 7.6% increase in turnover for 2025-2026, reaching 482.9 million euros, with strong growth in respiratory and home care activities.

Groupe Bastide exceeded its revenue guidance for 2025-2026, posting –527 million, driven by strong growth in home healthcare services and robust organic performance despite price cuts.

Bastide Le Confort Médical reported a 7.6% revenue increase to 482.9 million euros for 2025-2026, excluding the divested EXPERF, and expects to exceed 500 million euros in revenue for 2026-2027.

Bastide exceeded its revenue targets, growing 7.6% to —482.9 million from continuing operations, and expects to surpass —500 million next year with a 9% operating margin.

Bastide surpassed its 2025-2026 revenue goal, achieving 482.9 million euros and confirming a target operating margin of 9.0%, while also projecting over 500 million euros for 2026-2027.

This document outlines the Price to Earnings Forward for Bastide Le Confort Medical SA (EURONEXT:BLC).

Bastide le Confort Medical updated its share capital and voting rights, reporting 7,468,749 shares and 11,575,841 exercisable voting rights as of July 31, 2026.

Bastide Médical, a home medical comfort company, is recruiting in Occitanie and nationally.

Bastide Le Confort Medical is projected to have 3,946 employees worldwide by March 2026, an increase from 3,833 in 2023.